Advisory Commission on Childhood Vaccines Request for Nominations for Voting Members, 39517-39518 [05-13422]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 130 / Friday, July 8, 2005 / Notices
II. Selection Procedure
Any organization in the medical
device manufacturing industry wishing
to participate in the selection of a
nonvoting member to represent industry
on a particular panel should send a
letter stating that interest to the FDA
contact (see FOR FURTHER INFORMATION
CONTACT) within 30 days of publication
of this document. Persons who
nominate themselves as industry
representatives for the panels will not
participate in the selection process. It is,
therefore, recommended that
nominations be made by someone
within an organization, trade
association, or firm who is willing to
participate in the selection process.
Within the subsequent 30 days, FDA
will send a letter to each organization
and a list of all nominees along with
their resumes. The letter will state that
the interested organizations are
responsible for conferring with one
another to select a candidate, within 60
days after receiving the letter, to serve
as the nonvoting industry representative
on a particular device panel. If no
individual is selected within that 60
days, the Commissioner may select the
nonvoting member to represent industry
interests.
III. Application Procedure
Individuals may nominate themselves
or an organization representing the
medical device industry may nominate
one or more individuals to serve as a
nonvoting industry representative. A
current curriculum vitae (which
includes the nominee’s business
address, telephone number, and e-mail
address) and the name of the panel of
interest should be sent to the FDA
contact person (see FOR FURTHER
INFORMATION CONTACT). FDA will
forward all nominations to the
organizations that have expressed
interest in participating in the selection
process for that panel.
FDA has a special interest in ensuring
that women, minority groups,
individuals with disabilities, and small
businesses are adequately represented
on its advisory committees. Therefore,
the agency encourages nominations for
appropriately qualified candidates from
these groups.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: June 23, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External
Relations.
[FR Doc. 05–13421 Filed 7–7–05; 8:45 am]
BILLING CODE 4160–01–S
VerDate jul<14>2003
16:32 Jul 07, 2005
Jkt 205001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Commission on Childhood
Vaccines Request for Nominations for
Voting Members
Health Resources and Services
Administration, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The Health Resources and
Services Administration (HRSA) is
requesting nominations to fill three
vacancies on the Advisory Commission
on Childhood Vaccines (ACCV). The
ACCV was established by Title XXI of
the Public Health Service Act (the Act),
as enacted by Public Law (Pub. L.) 99–
660 and as subsequently amended, and
advises the Secretary of Health and
Human Services (the Secretary) on
issues related to implementation of the
National Vaccine Injury Compensation
Program (VICP).
DATES: The agency must receive
nominations on or before August 8,
2005.
All nominations are to be
submitted to the Acting Director,
Division of Vaccine Injury
Compensation, Healthcare Systems
Bureau, HRSA, Parklawn Building,
Room 11C–26, 5600 Fishers Lane,
Rockville, Maryland 20857.
FOR FURTHER INFORMATION CONTACT: Ms.
Cheryl A. Lee, Principal Staff Liaison,
Policy Analysis Branch, Division of
Vaccine Injury Compensation, HSB,
HRSA, at (301) 443–2124 or e-mail:
clee@hrsa.gov.
ADDRESSES:
Under the
authorities that established the ACCV,
the Federal Advisory Committee Act of
October 6, 1972 (Pub. L. 92–463), and
section 2119 of the Act, 42 U.S.C.
300aa–19, as added by Pub. L. 99–660
and amended, HRSA is requesting
nominations for three voting members
of the ACCV.
The ACCV advises the Secretary on
the implementation of the VICP. The
activities of the ACCV include:
recommending changes in the Vaccine
Injury Table at its own initiative or as
the result of the filing of a petition;
advising the Secretary in implementing
section 2127 regarding the need for
childhood vaccination products that
result in fewer or no significant adverse
reactions; surveying Federal, State, and
local programs and activities related to
gathering information on injuries
associated with the administration of
childhood vaccines, including the
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
39517
adverse reaction reporting requirements
of section 2125(b); advising the
Secretary on the methods of obtaining,
compiling, publishing, and using
credible data related to the frequency
and severity of adverse reactions
associated with childhood vaccines; and
recommending to the Director of the
National Vaccine Program that vaccine
safety research be conducted on various
vaccine injuries.
The ACCV consists of nine voting
members appointed by the Secretary as
follows: Three health professionals, who
are not employees of the United States
Government and have expertise in the
health care of children; and the
epidemiology, etiology, and prevention
of childhood diseases; and the adverse
reactions associated with vaccines, at
least two shall be pediatricians; three
members from the general public, at
least two shall be legal representatives
(parents or guardians) of children who
have suffered a vaccine-related injury or
death; and three attorneys, at least one
shall be an attorney whose specialty
includes representation of persons who
have suffered a vaccine-related injury or
death, and one shall be an attorney
whose specialty includes representation
of vaccine manufacturers. In addition,
the Director of the National Institutes of
Health, the Assistant Secretary for
Health, the Director of the Centers for
Disease Control and Prevention, and the
Commissioner of the Food and Drug
Administration (or the designees of such
officials) serve as nonvoting ex officio
members.
Specifically, HRSA is requesting
nominations for three voting members
of the ACCV representing: (1) A health
professional, who has expertise in the
health care of children; and the
epidemiology, etiology, and prevention
of childhood diseases; (2) an attorney
with no specific affiliation; and (3) a
legal representative (parent or guardian)
of a child who has suffered a vaccinerelated injury or death. Nominees will
be invited to serve a 3-year term
beginning January 1, 2006, and ending
December 31, 2008.
Interested persons may nominate one
or more qualified persons for
membership on the ACCV. Nominations
shall state that the nominee is willing to
serve as a member of the ACCV and
appears to have no conflict of interest
that would preclude the ACCV
membership. Potential candidates will
be asked to provide detailed information
concerning consultancies, research
grants, or contracts to permit evaluation
of possible sources of conflicts of
interest. A curriculum vitae or resume
should be submitted with the
nomination.
E:\FR\FM\08JYN1.SGM
08JYN1
39518
Federal Register / Vol. 70, No. 130 / Friday, July 8, 2005 / Notices
The Department of Health and Human
Services has special interest in assuring
that women, minority groups, and the
physically disabled are adequately
represented on advisory committees;
and therefore, extends particular
encouragement to nominations for
appropriately qualified female,
minority, or disabled candidates.
Dated: June 30, 2005.
Steven A. Pelovitz,
Associate Administrator for Administration
and Financial Management.
[FR Doc. 05–13422 Filed 7–7–05; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel.
Date: July 14, 2005.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5635
Fishers Lane, Bethesda, MD 20892,
(Telephone conference call.)
Contact Person: Rudy O. Pozzatti, PhD,
Scientific Review Administrator, Office of
Scientific Review, National Human Genome
Research Institute, National Institutes of
Health, Bethesda, MD 20892. 301–402–0838.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: June 28, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–13448 Filed 7–7–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Child Health and
Human Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel, Requirements of
BMP–SMAD1/5 Pathway in ES Cell SelfRenewal.
Date: July 25, 2005.
Time: 3:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Room 5B01, Rockville,
MD 20852. (Telephone conference call.)
Contact Person: Jon M. Ranhand, PhD,
Scientist Review Administrator, Division of
Scientific Review, National Institute of Child
Health and Human Development, NIH, 6100
Executive Boulevard, Room 5B01, Bethesda,
MD 20892, (301) 435–6884,
ranhandj@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: June 28, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–13447 Filed 7–7–05; 8:45 am]
BILLING CODE 4140–01–M
VerDate jul<14>2003
16:32 Jul 07, 2005
Jkt 205001
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel, Member
Conflict Meeting.
Date: July 20, 2005.
Time: 4 p.m to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Mark Swieter, PhD, Chief,
Training and Special Projects Review Branch,
Office of Extramural Affairs, National
Institute on Drug Abuse, NIH, DHHS, 6101
Executive Boulevard, Suite 220, Bethesda,
MD 20892–8401. (301) 435–1389.
ms80x@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel, HIV and
Drug Abuse Interventions Among Pregnant
Women in Drug Abuse Treatment.
Date: July 26, 2005.
Time: 8:30 a.m to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Madison Hotel, 1177 15th St.,
NW., Washington, DC 20005.
Contact Person: Mark Swieter, PhD, Chief,
Training and Special Projects Review Branch,
Office of Extramural Affairs, National
Institute on Drug Abuse, NIH, DHHS, 6101
Executive Boulevard, Suite 220, Bethesda,
MD 20892–8401. (301) 435–1389.
ms80x@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse Research
Programs, National Institutes of Health, HHS)
E:\FR\FM\08JYN1.SGM
08JYN1
]]>Agencies
[Federal Register Volume 70, Number 130 (Friday, July 8, 2005)]
[Notices]
[Pages 39517-39518]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-13422]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Advisory Commission on Childhood Vaccines Request for Nominations
for Voting Members
AGENCY: Health Resources and Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Health Resources and Services Administration (HRSA) is
requesting nominations to fill three vacancies on the Advisory
Commission on Childhood Vaccines (ACCV). The ACCV was established by
Title XXI of the Public Health Service Act (the Act), as enacted by
Public Law (Pub. L.) 99-660 and as subsequently amended, and advises
the Secretary of Health and Human Services (the Secretary) on issues
related to implementation of the National Vaccine Injury Compensation
Program (VICP).
DATES: The agency must receive nominations on or before August 8, 2005.
ADDRESSES: All nominations are to be submitted to the Acting Director,
Division of Vaccine Injury Compensation, Healthcare Systems Bureau,
HRSA, Parklawn Building, Room 11C-26, 5600 Fishers Lane, Rockville,
Maryland 20857.
FOR FURTHER INFORMATION CONTACT: Ms. Cheryl A. Lee, Principal Staff
Liaison, Policy Analysis Branch, Division of Vaccine Injury
Compensation, HSB, HRSA, at (301) 443-2124 or e-mail: clee@hrsa.gov.
SUPPLEMENTARY INFORMATION: Under the authorities that established the
ACCV, the Federal Advisory Committee Act of October 6, 1972 (Pub. L.
92-463), and section 2119 of the Act, 42 U.S.C. 300aa-19, as added by
Pub. L. 99-660 and amended, HRSA is requesting nominations for three
voting members of the ACCV.
The ACCV advises the Secretary on the implementation of the VICP.
The activities of the ACCV include: recommending changes in the Vaccine
Injury Table at its own initiative or as the result of the filing of a
petition; advising the Secretary in implementing section 2127 regarding
the need for childhood vaccination products that result in fewer or no
significant adverse reactions; surveying Federal, State, and local
programs and activities related to gathering information on injuries
associated with the administration of childhood vaccines, including the
adverse reaction reporting requirements of section 2125(b); advising
the Secretary on the methods of obtaining, compiling, publishing, and
using credible data related to the frequency and severity of adverse
reactions associated with childhood vaccines; and recommending to the
Director of the National Vaccine Program that vaccine safety research
be conducted on various vaccine injuries.
The ACCV consists of nine voting members appointed by the Secretary
as follows: Three health professionals, who are not employees of the
United States Government and have expertise in the health care of
children; and the epidemiology, etiology, and prevention of childhood
diseases; and the adverse reactions associated with vaccines, at least
two shall be pediatricians; three members from the general public, at
least two shall be legal representatives (parents or guardians) of
children who have suffered a vaccine-related injury or death; and three
attorneys, at least one shall be an attorney whose specialty includes
representation of persons who have suffered a vaccine-related injury or
death, and one shall be an attorney whose specialty includes
representation of vaccine manufacturers. In addition, the Director of
the National Institutes of Health, the Assistant Secretary for Health,
the Director of the Centers for Disease Control and Prevention, and the
Commissioner of the Food and Drug Administration (or the designees of
such officials) serve as nonvoting ex officio members.
Specifically, HRSA is requesting nominations for three voting
members of the ACCV representing: (1) A health professional, who has
expertise in the health care of children; and the epidemiology,
etiology, and prevention of childhood diseases; (2) an attorney with no
specific affiliation; and (3) a legal representative (parent or
guardian) of a child who has suffered a vaccine-related injury or
death. Nominees will be invited to serve a 3-year term beginning
January 1, 2006, and ending December 31, 2008.
Interested persons may nominate one or more qualified persons for
membership on the ACCV. Nominations shall state that the nominee is
willing to serve as a member of the ACCV and appears to have no
conflict of interest that would preclude the ACCV membership. Potential
candidates will be asked to provide detailed information concerning
consultancies, research grants, or contracts to permit evaluation of
possible sources of conflicts of interest. A curriculum vitae or resume
should be submitted with the nomination.
[[Page 39518]]
The Department of Health and Human Services has special interest in
assuring that women, minority groups, and the physically disabled are
adequately represented on advisory committees; and therefore, extends
particular encouragement to nominations for appropriately qualified
female, minority, or disabled candidates.
Dated: June 30, 2005.
Steven A. Pelovitz,
Associate Administrator for Administration and Financial Management.
[FR Doc. 05-13422 Filed 7-7-05; 8:45 am]
BILLING CODE 4165-15-P
